RECORDATI : RECORDATI RENCONTRE LES ANALYSTES FINANCIERS ET LA PRESSE SPECIALISEE A MILAN

Milan, le 27 avril 2010 - Recordati S.p.A. organise une rencontre avec les analystes financiers et la presse spécialisée le :


jeudi 6 mai 2010 à 16h00

Palazzo Mezzanotte

Piazza degli Affari, 6 - Milan

L'objectif de cette rencontre est de présenter les résultats du 1er trimestre 2010, la stratégie de développement du Groupe et les objectifs pour la période 2010-2012.

Vous pourrez également participer à la rencontre par conférence téléphonique grâce à sa traduction simultanée en anglais. Les numéros de téléphone et le code d'accès sont les suivants :

Italie : +39 02 36005955

Royaume-Uni : +44 (0) 1452587427

Etats-Unis : +18665516755

France : +33 (0) 170751217

Allemagne : +49 (0) 6922227071

ID to access the call in the English language: 71717137

Callers are invited to dial-in 10 minutes before conference time. A recording of the conference call will be subsequently placed on the website:

http://www.recordati.com/rec_en/investors/presentations/

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2009 was E 747.5 million, operating income was E 162.2 million and net income was E 110.6 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media Relations

Marianne Tatschke
(39)0248787393
e-mail: [email protected]

Claudio Rossetti (Echo Comunicazione d'Impresa)
(39)02 62694736
e-mail: [email protected]

Copyright Hugin

Ce communiqué de presse est diffusé par Hugin. L'émetteur est seul responsable du contenu de ce communiqué.

[CN#165477]